tiprankstipranks
Trending News
More News >

Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer

Oppenheimer analyst Jeff Jones lowered the firm’s price target on Chemomab Therapeutics (CMMB) to $10 from $11 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, highlighting recent updates, including regulatory feedback providing clear guidance on approvable endpoints for nebokitug in PSC, and recent positive 48 weeks SPRING OLE results.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1